Category - Developments

3D Signatures (TSX-V:DXD) presented preliminary results of a collaborative initiative between the company and the Institut Universitaire de Cardiologie et de Pneumologie De Quebec, exploring the possibility of...

Neovasc (NASDAQ:NVCN) provided an update on the clinical experience with its Tiara transcatheter mitral valve, sending the shares up 50% to $2.14 at midday Dec 6. Tiara is a novel transcatheter device designed to treat...

MaRS Innovation and the Korea Health Industry Development Institute (KHIDI) signed a five-year global partnership agreement to commercialize the latest advances in biomedical and healthcare innovations, which is...

Oramed Pharmaceuticals (NASDAQ:ORMP) has successfully concluded a Phase 1b study of ORMD-0901, its oral GLP-1 analog, in Type 2 diabetes patients. The study showed ORMD-0901 to be safe and well tolerated, having no...

Titan Pharmaceuticals’ (NASDAQ:TTNP) Probuphine implant was named a gold award winner at the 13th annual Stevie Awards for Women in Business in the category of “Best New Product or Service of the Year.”...

Britain’s Computer Business Review has selected Titan Pharmaceuticals’ (NASDAQ:TTNP) Probuphine implant as one of 10 future technologies that will change the world, along with autonomous vehicles, bionic exoskeletons...

Profound Medical (TSX-V:PRN) has completed a bought deal offering of 15.82 million common shares at a price of $1.10 each for gross proceeds of about $17.4-million. The offering was completed through a syndicate of...

Avivagen (TSX-V:VIV) has signed an agreement with Shaanxi Jintai Mining, a widely diversified Chinese company, to form a joint venture company to commercialize OxC-beta Livestock in China. The JV will initially target...

BioTuesdays’ Stephen Kilmer joins Titan management, directors and guests at the bell closing ceremony. Katherine Beebe, executive VP and chief development officer of Titan Pharmaceuticals (NASDAQ:TTNP)...

After an end-of-Phase 2 meeting with the FDA, Aurinia Pharmaceuticals (NASDAQ:AUPH) plans to begin a single Phase 3 clinical trial for voclosporin in the treatment of lupus nephritis (LN). Aurinia believes the Phase 3...